<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Cyclacel Pharmaceuticals Inc — News on 6ix</title>
<link>https://6ix.com/company/cyclacel-pharmaceuticals-inc</link>
<description>Latest news and press releases for Cyclacel Pharmaceuticals Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 02 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/cyclacel-pharmaceuticals-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68355b7478dffbe2df0ebe7c.webp</url>
<title>Cyclacel Pharmaceuticals Inc</title>
<link>https://6ix.com/company/cyclacel-pharmaceuticals-inc</link>
</image>
<item>
<title>FF Announces Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/cyclacel-pharmaceuticals-inc/news/ff-announces-fourth-quarter-and-full-year-2025-financial-results-13</link>
<guid isPermaLink="true">https://6ix.com/company/cyclacel-pharmaceuticals-inc/news/ff-announces-fourth-quarter-and-full-year-2025-financial-results-13</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>LOS ANGELES, April 2, 2026 /PRNewswire/ -- Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) ("FF," "Faraday Future," or the "Company"), a</description>
</item>
<item>
<title>IDEX Corporation to Webcast First Quarter 2026 Earnings Call</title>
<link>https://6ix.com/company/cyclacel-pharmaceuticals-inc/news/idex-corporation-to-webcast-first-quarter-2026-earnings-call-6</link>
<guid isPermaLink="true">https://6ix.com/company/cyclacel-pharmaceuticals-inc/news/idex-corporation-to-webcast-first-quarter-2026-earnings-call-6</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>NORTHBROOK, Ill.--(BUSINESS WIRE)-- IDEX Corporation (NYSE:IEX) announced today that it will release its first quarter 2026 results on Wednesday, April 29,</description>
</item>
<item>
<title>Sonic Automotive Schedules Release of First Quarter and 2026 Financial Results</title>
<link>https://6ix.com/company/cyclacel-pharmaceuticals-inc/news/sonic-automotive-schedules-release-of-first-quarter-and-2026-financial-results-3</link>
<guid isPermaLink="true">https://6ix.com/company/cyclacel-pharmaceuticals-inc/news/sonic-automotive-schedules-release-of-first-quarter-and-2026-financial-results-3</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>CHARLOTTE, N.C.--(BUSINESS WIRE)-- Sonic Automotive, Inc. (“Sonic Automotive” or “Sonic” or the “Company”) (NYSE:SAH), one of the nation’s largest automotive</description>
</item>
<item>
<title>Endeavour To Announce Its Q1 2026 Results On 30 April 2026</title>
<link>https://6ix.com/company/cyclacel-pharmaceuticals-inc/news/endeavour-to-announce-its-q1-2026-results-on-30-april-2026-16</link>
<guid isPermaLink="true">https://6ix.com/company/cyclacel-pharmaceuticals-inc/news/endeavour-to-announce-its-q1-2026-results-on-30-april-2026-16</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>ENDEAVOUR TO ANNOUNCE ITS Q1 2026 RESULTS ON 30 APRIL 2026 London, 2 April 2026 – Endeavour Mining plc (LSE:EDV, TSX:EDV, OTCQX:EDVMF) expects to release its</description>
</item>
<item>
<title>N‑able Expands Its Technology Alliance Program with New Integrations, Advancing Incident Response and Hyperautomation</title>
<link>https://6ix.com/company/cyclacel-pharmaceuticals-inc/news/nable-expands-its-technology-alliance-program-with-new-integrations-advancing-incident-response-and-hyperautomation-4</link>
<guid isPermaLink="true">https://6ix.com/company/cyclacel-pharmaceuticals-inc/news/nable-expands-its-technology-alliance-program-with-new-integrations-advancing-incident-response-and-hyperautomation-4</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>New integrations empower MSPs and customers to automate complex security workflows and accelerate recovery from ransomware attacks BURLINGTON,</description>
</item>
<item>
<title>GFL Environmental Inc. Announces 10% Increase to Quarterly Dividend</title>
<link>https://6ix.com/company/cyclacel-pharmaceuticals-inc/news/gfl-environmental-inc-announces-10percent-increase-to-quarterly-dividend-6</link>
<guid isPermaLink="true">https://6ix.com/company/cyclacel-pharmaceuticals-inc/news/gfl-environmental-inc-announces-10percent-increase-to-quarterly-dividend-6</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>MIAMI BEACH, FL, April 2, 2026 /PRNewswire/ - GFL Environmental Inc. (NYSE: GFL) (TSX: GFL) ("GFL" or the "Company") today announced that the Board of</description>
</item>
<item>
<title>InterContinental Hotels Group PLC Announces Transaction in Own Shares - April 02</title>
<link>https://6ix.com/company/cyclacel-pharmaceuticals-inc/news/intercontinental-hotels-group-plc-announces-transaction-in-own-shares-april-02-19</link>
<guid isPermaLink="true">https://6ix.com/company/cyclacel-pharmaceuticals-inc/news/intercontinental-hotels-group-plc-announces-transaction-in-own-shares-april-02-19</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>InterContinental Hotels Group PLC (the "Company")Purchase of own shares LONDON, UK / ACCESS Newswire / April 2, 2026 / The Company announces that on 01 April</description>
</item>
<item>
<title>Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus), an Investigational Bispecific Tie2 Agonist/VEGF Inhibitor, for the Treatment of Neovascular Age-Related Macular Degeneration</title>
<link>https://6ix.com/company/cyclacel-pharmaceuticals-inc/news/merck-announces-initiation-of-pivotal-phase-2b3-trial-evaluating-mk-8748-tiespectus-an-investigational-bispecific-tie2-agonistvegf-inhibitor-for-the-treatment-of-neovascular-age-related-macular-degeneration-2</link>
<guid isPermaLink="true">https://6ix.com/company/cyclacel-pharmaceuticals-inc/news/merck-announces-initiation-of-pivotal-phase-2b3-trial-evaluating-mk-8748-tiespectus-an-investigational-bispecific-tie2-agonistvegf-inhibitor-for-the-treatment-of-neovascular-age-related-macular-degeneration-2</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of a pivotal Phase</description>
</item>
<item>
<title>AngioDynamics Reports Fiscal Year 2026 Third Quarter Financial Results; Sustained Double-Digit Med Tech Growth Drives Continued Profitability</title>
<link>https://6ix.com/company/cyclacel-pharmaceuticals-inc/news/angiodynamics-reports-fiscal-year-2026-third-quarter-financial-results-sustained-double-digit-med-tech-growth-drives-continued-profitability-5</link>
<guid isPermaLink="true">https://6ix.com/company/cyclacel-pharmaceuticals-inc/news/angiodynamics-reports-fiscal-year-2026-third-quarter-financial-results-sustained-double-digit-med-tech-growth-drives-continued-profitability-5</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>Med Tech segment delivered its sixth consecutive quarter of double-digit growth Strong adjusted EBITDA Third consecutive quarter the Company raised full year</description>
</item>
<item>
<title>Sally Beauty Holdings Appoints Adrianne Lee as Chief Financial Officer</title>
<link>https://6ix.com/company/cyclacel-pharmaceuticals-inc/news/sally-beauty-holdings-appoints-adrianne-lee-as-chief-financial-officer-2</link>
<guid isPermaLink="true">https://6ix.com/company/cyclacel-pharmaceuticals-inc/news/sally-beauty-holdings-appoints-adrianne-lee-as-chief-financial-officer-2</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>Marlo Cormier to Step Down to Pursue Other Opportunities Reaffirms Second Quarter and Fiscal Year 2026 Guidance PLANO, Texas--(BUSINESS WIRE)-- Sally Beauty</description>
</item>
<item>
<title>Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)</title>
<link>https://6ix.com/company/cyclacel-pharmaceuticals-inc/news/roivant-announces-expansion-of-brepocitinib-development-program-with-new-phase-2b3-trial-in-lichen-planopilaris-lpp-and-phase-3-study-results-for-batoclimab-in-thyroid-eye-disease-ted-8</link>
<guid isPermaLink="true">https://6ix.com/company/cyclacel-pharmaceuticals-inc/news/roivant-announces-expansion-of-brepocitinib-development-program-with-new-phase-2b3-trial-in-lichen-planopilaris-lpp-and-phase-3-study-results-for-batoclimab-in-thyroid-eye-disease-ted-8</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>Lichen planopilaris (LPP) is a highly morbid inflammatory scalp disorder that causes generally irreversible scarring hair loss, often accompanied by profound</description>
</item>
<item>
<title>Global Net Lease, Inc. Announces Retirement of Two Board Members</title>
<link>https://6ix.com/company/cyclacel-pharmaceuticals-inc/news/global-net-lease-inc-announces-retirement-of-two-board-members-11</link>
<guid isPermaLink="true">https://6ix.com/company/cyclacel-pharmaceuticals-inc/news/global-net-lease-inc-announces-retirement-of-two-board-members-11</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>NEW YORK, April 02, 2026 (GLOBE NEWSWIRE) -- Global Net Lease, Inc. (“GNL” or the “Company”) today announced that Sue Perrotty and Governor Edward Rendell</description>
</item>
<item>
<title>ESAB Corporation Announces CFO Transition</title>
<link>https://6ix.com/company/cyclacel-pharmaceuticals-inc/news/esab-corporation-announces-cfo-transition-6</link>
<guid isPermaLink="true">https://6ix.com/company/cyclacel-pharmaceuticals-inc/news/esab-corporation-announces-cfo-transition-6</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>Appoints R. Brent Jones CFO Reaffirms 2026 Outlook NORTH BETHESDA, Md.--(BUSINESS WIRE)-- ESAB Corporation ("ESAB" or the "Company") (NYSE: ESAB), a focused</description>
</item>
<item>
<title>Innate Pharma Files Its 2025 Universal Registration Document (Document D’enregistrement Universel) and 2025 Form 20-f Annual Report</title>
<link>https://6ix.com/company/cyclacel-pharmaceuticals-inc/news/innate-pharma-files-its-2025-universal-registration-document-document-denregistrement-universel-and-2025-form-20-f-annual-report-13</link>
<guid isPermaLink="true">https://6ix.com/company/cyclacel-pharmaceuticals-inc/news/innate-pharma-files-its-2025-universal-registration-document-document-denregistrement-universel-and-2025-form-20-f-annual-report-13</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the</description>
</item>
<item>
<title>Skeena Gold & Silver Announces Pricing of US$750 Million Senior Secured Notes Offering to Refinance Former Project Financing and to Fund Partial Buyback of Existing Gold Stream</title>
<link>https://6ix.com/company/cyclacel-pharmaceuticals-inc/news/skeena-gold-and-silver-announces-pricing-of-usdollar750-million-senior-secured-notes-offering-to-refinance-former-project-financing-and-to-fund-partial-buyback-of-existing-gold-stream-3</link>
<guid isPermaLink="true">https://6ix.com/company/cyclacel-pharmaceuticals-inc/news/skeena-gold-and-silver-announces-pricing-of-usdollar750-million-senior-secured-notes-offering-to-refinance-former-project-financing-and-to-fund-partial-buyback-of-existing-gold-stream-3</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>VANCOUVER, British Columbia, April 02, 2026 (GLOBE NEWSWIRE) -- Skeena Resources Limited (TSX: SKE, NYSE: SKE) (“Skeena Gold & Silver”, “Skeena” or the</description>
</item>
<item>
<title>Costamare Inc. Declares Quarterly Dividend on Its Preferred and Common Stock</title>
<link>https://6ix.com/company/cyclacel-pharmaceuticals-inc/news/costamare-inc-declares-quarterly-dividend-on-its-preferred-and-common-stock-8</link>
<guid isPermaLink="true">https://6ix.com/company/cyclacel-pharmaceuticals-inc/news/costamare-inc-declares-quarterly-dividend-on-its-preferred-and-common-stock-8</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>MONACO, April 02, 2026 (GLOBE NEWSWIRE) -- Costamare Inc. (the “Company”) (NYSE: CMRE) has declared cash dividends of US $0.476563 per share on its 7.625%</description>
</item>
<item>
<title>Alamos Gold Provides Notice of First Quarter 2026 Results and Conference Call, and Annual General Meeting of Shareholders</title>
<link>https://6ix.com/company/cyclacel-pharmaceuticals-inc/news/alamos-gold-provides-notice-of-first-quarter-2026-results-and-conference-call-and-annual-general-meeting-of-shareholders</link>
<guid isPermaLink="true">https://6ix.com/company/cyclacel-pharmaceuticals-inc/news/alamos-gold-provides-notice-of-first-quarter-2026-results-and-conference-call-and-annual-general-meeting-of-shareholders</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>All amounts are in United States dollars, unless otherwise stated. TORONTO, April 02, 2026 (GLOBE NEWSWIRE) -- Alamos Gold Inc. (TSX:AGI; NYSE:AGI) (“Alamos”</description>
</item>
<item>
<title>Pharvaris Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/cyclacel-pharmaceuticals-inc/news/pharvaris-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update-3</link>
<guid isPermaLink="true">https://6ix.com/company/cyclacel-pharmaceuticals-inc/news/pharvaris-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update-3</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>Enrollment completed in CHAPTER-3, a pivotal study of deucrictibant XR for prophylactic treatment of HAE attacks; topline data anticipated in 3Q2026Timeline</description>
</item>
<item>
<title>Scorpio Tankers Inc. Announces Strategic Collaboration with AMPERA, Inc. to Develop & Commercialize Micronuclear Solutions for Global Marine and Shipping Markets</title>
<link>https://6ix.com/company/cyclacel-pharmaceuticals-inc/news/scorpio-tankers-inc-announces-strategic-collaboration-with-ampera-inc-to-develop-and-commercialize-micronuclear-solutions-for-global-marine-and-shipping-markets-4</link>
<guid isPermaLink="true">https://6ix.com/company/cyclacel-pharmaceuticals-inc/news/scorpio-tankers-inc-announces-strategic-collaboration-with-ampera-inc-to-develop-and-commercialize-micronuclear-solutions-for-global-marine-and-shipping-markets-4</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>MONACO, April 02, 2026 (GLOBE NEWSWIRE) -- Scorpio Tankers Inc. (NYSE:STNG) (“Scorpio Tankers” or the “Company”) announced that it has entered into a</description>
</item>
<item>
<title>Top Ships Announces Filing of 2025 Annual Report on Form 20-F</title>
<link>https://6ix.com/company/cyclacel-pharmaceuticals-inc/news/top-ships-announces-filing-of-2025-annual-report-on-form-20-f-11</link>
<guid isPermaLink="true">https://6ix.com/company/cyclacel-pharmaceuticals-inc/news/top-ships-announces-filing-of-2025-annual-report-on-form-20-f-11</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>ATHENS, Greece, April 02, 2026 (GLOBE NEWSWIRE) -- TOP Ships Inc. (the “Company”), an international owner and operator of modern, fuel efficient "ECO" tanker</description>
</item>
</channel>
</rss>